Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-RIC Regimen Before Haplo-SCT for Older/Frail AML Patients
NCT07598110Phase 2Not yet recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of fludarabine, treosulfan in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
fludarabinetreosulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07598110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598110.